Lido Advisors
INDV icon

Lido Advisors’s Indivior Pharmaceuticals INDV Stock Holding History

Lido Advisors’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$559K Buy
+13,628
New +$494K ﹤0.01% 1409
2026
Q1 		– Sell
-11,452
Closed -$276K – 2036
2025
Q4 		$276K Hold
11,452
– – ﹤0.01% 1607
2025
Q3 		$276K Buy
+11,452
New +$240K ﹤0.01% 1529

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lido Advisors's INDV Position: Q2 2026 in Review

Lido Advisors opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 13,628 shares worth $559K. The stake represents ﹤0.01% of the portfolio and ranks #1409 among its holdings. This is a return to the name: Lido Advisors previously reported a position in INDV as recently as Q4 2025.

Lido Advisors first reported a position in INDV in Q3 2025 and has held it in 3 quarters since. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Lido Advisors held 13,628 shares of Indivior Pharmaceuticals worth $559K as of Q2 2026.
  • Indivior Pharmaceuticals was a new Lido Advisors position in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #1409 holding.
  • Lido Advisors first reported a position in Indivior Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.